312 related articles for article (PubMed ID: 29264709)
1. Integration of pro- and anti-angiogenic signals by endothelial cells.
Kazerounian S; Lawler J
J Cell Commun Signal; 2018 Mar; 12(1):171-179. PubMed ID: 29264709
[TBL] [Abstract][Full Text] [Related]
2. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data.
Natale G; Bocci G
Cancer Lett; 2018 Sep; 432():28-37. PubMed ID: 29885517
[TBL] [Abstract][Full Text] [Related]
3. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor.
Laderoute KR; Alarcon RM; Brody MD; Calaoagan JM; Chen EY; Knapp AM; Yun Z; Denko NC; Giaccia AJ
Clin Cancer Res; 2000 Jul; 6(7):2941-50. PubMed ID: 10914744
[TBL] [Abstract][Full Text] [Related]
4. The angiogenic switch: implications in the regulation of tumor dormancy.
Moserle L; Amadori A; Indraccolo S
Curr Mol Med; 2009 Nov; 9(8):935-41. PubMed ID: 19925406
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
Tanaka K; Sonoo H; Kurebayashi J; Nomura T; Ohkubo S; Yamamoto Y; Yamamoto S
Clin Cancer Res; 2002 May; 8(5):1125-31. PubMed ID: 12006528
[TBL] [Abstract][Full Text] [Related]
8. Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularization in renal cell carcinoma and other malignancies.
Moccia F; Dragoni S; Poletto V; Rosti V; Tanzi F; Ganini C; Porta C
Anticancer Agents Med Chem; 2014 Feb; 14(2):296-312. PubMed ID: 23869775
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of angiogenic factors in breast cancer.
Locopo N; Fanelli M; Gasparini G
Breast Cancer Res Treat; 1998; 52(1-3):159-73. PubMed ID: 10066080
[TBL] [Abstract][Full Text] [Related]
10. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
Indraccolo S
Adv Exp Med Biol; 2013; 734():37-52. PubMed ID: 23143974
[TBL] [Abstract][Full Text] [Related]
11. The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.
Reiher FK; Ivanovich M; Huang H; Smith ND; Bouck NP; Campbell SC
J Urol; 2001 Jun; 165(6 Pt 1):2075-81. PubMed ID: 11371931
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.
Kwak C; Jin RJ; Lee C; Park MS; Lee SE
BJU Int; 2002 Feb; 89(3):303-9. PubMed ID: 11856116
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
14. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism.
Hawighorst T; Velasco P; Streit M; Hong YK; Kyriakides TR; Brown LF; Bornstein P; Detmar M
EMBO J; 2001 Jun; 20(11):2631-40. PubMed ID: 11387198
[TBL] [Abstract][Full Text] [Related]
15. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
Siveen KS; Prabhu K; Krishnankutty R; Kuttikrishnan S; Tsakou M; Alali FQ; Dermime S; Mohammad RM; Uddin S
Curr Vasc Pharmacol; 2017; 15(4):339-351. PubMed ID: 28056756
[TBL] [Abstract][Full Text] [Related]
16. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.
Kay NE; Bone ND; Tschumper RC; Howell KH; Geyer SM; Dewald GW; Hanson CA; Jelinek DF
Leukemia; 2002 May; 16(5):911-9. PubMed ID: 11986954
[TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
18. Angiogenic factors in chronic lymphocytic leukemia.
Xia Y; Lu RN; Li J
Leuk Res; 2012 Oct; 36(10):1211-7. PubMed ID: 22727510
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs in tumor angiogenesis.
Wang W; Zhang E; Lin C
Life Sci; 2015 Sep; 136():28-35. PubMed ID: 26144623
[TBL] [Abstract][Full Text] [Related]
20. Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.
Kim DS; Franklyn JA; Stratford AL; Boelaert K; Watkinson JC; Eggo MC; McCabe CJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1119-28. PubMed ID: 16394085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
